DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions

Information source: Kremers Urban Development Company
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Bicalutamide (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Kremers Urban Development Company

Official(s) and/or principal investigator(s):
Benoit Girard, M.D., Principal Investigator, Affiliation: SFBC Anapharm

Summary

The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablet (test) versus Casodex® (reference), administered as 1 x 50 mg tablet under fed conditions.

Clinical Details

Official title: Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome:

AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

Eligibility

Minimum age: 19 Years. Maximum age: 70 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Male, non-smoker, 18 years of age and older;

- Capable of consent;

- BMI≥19. 0 and <30. 0 kg/m2.

Exclusion Criteria:

- Clinically significant illnesses within 4 weeks prior to the administration of

the study medication.

- Clinically significant surgery within 4 weeks prior to the administration of the

study medication.

- Any clinically significant abnormality found during medical screening.

- Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the

subject from participating in the study.

- Abnormal laboratory tests judged clinically significant.

- Positive testing for hepatitis B, hepatitis C, or HIV at screening.

- ECG abnormalities (clinically significant) or vital sign abnormalities (systolic

blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.

- History of significant alcohol abuse or drug abuse within one year prior to the

screening visit.

- Regular use of alcohol within six months prior to the screening visit (more than

fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).

- Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or

hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug screen at screening.

- History of allergic reactions to heparin, bicalutamide, or other related drugs.

- Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of

inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.

- Use of an investigational drug or participation in an investigational study within 30

days prior to administration of the study medication.

- Clinically significant history or presence of any clinically significant

gastrointestinal pathology (e. g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e. g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.

- Any clinically significant history or presence of clinically significant

neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.

- Use of prescription medication within 14 days prior to administration of study

medication or over-the-counter products (including natural food supplements, vitamins. garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.

- Difficulty to swallow study medication.

- Use of any tobacco products in the 6 months preceding drug administration.

- Any food allergy, intolerance, restriction or special diet that, in the opinion of

the Medical Sub-Investigator, could contraindicate the subject's participation in this study.

- A depot injection or an implant of any drug within 3 months prior to administration

of study medication.

- Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or

loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:

- 50 mL to 300 mL of whole blood within 30 days,

- 301 mL to 500 mL of whole blood within 45 days, or

- more than 500 mL of whole blood within 56 days prior to drug administration.

Locations and Contacts

SFBC Anapharm, sainte-Foy, Quebec G1V 2K8, Canada
Additional Information

Starting date: May 2005
Last updated: February 28, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017